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Osteoporosis and osteopenia are common worldwide problems leading to potentially 
life-threatening consequences. Omega-3 supplementation for treating osteoporosis is less 
studied and less valued by physicians. We aimed to ascertain the appropriate dosage of ome-
ga-3 supplementation to prevent osteoporosis. Google scholar database was searched in May 
2017 using the key words: n-3 fatty acids, omega-3 polyunsaturated fatty acids, essential 
fatty acids, eicosapentaenoic fatty acids, docosahexaenoic acid, docosapentaenoic acid, al-
pha linolenic acid, linoleic acid, osteopenia, osteoporosis, bone density, and fracture. We 
reviewed English language reports of randomized controlled trials with intake of omega-3 
polyunsaturated fatty acids, in which subjects were over 60 years and supplemented with a 
quantified dosage of omega-3; and outcome was indicated by bone mineral densitometry 
medical record of fractures and radiological imaging, and serum biomarker to evaluate bone 
metabolism. We reviewed 110 papers, which only eight articles met our conclusion criteria 
and concluded with curative effects. Three articles came up with no prophylactic or curative 
effect of omega-3 supplementation, three articles suggested a dosage of omega-3 supple-
ment that non-significantly increased bone mineral densitometry or decreased absorption, 
and thus, had prophylactic effects. One article just concluded the positive effects, not defin-
ing the exact results. It is suggested that a dosage of 4.5 to 6 g/d of eicosapentaenoic acid and 
docosahexaenoic acid can have curative effects, while 900-1000 mg/d can have prophylactic 
outcomes. N-3 fatty acids have positive effects on bone density, but to confine definitive 
dosage and formulation of omega-3 supplementation for reducing the risk of osteoporosis, 
further investigations are required. 
  
 
INTRODUCTION
Osteoporosis is actually defined as bone strength reduction 
due to the loss of bone tissue and deterioration in skeletal 
microarchitecture because of which the bone is at a high-
er risk of fragility fracture (1). The major complication of 
osteoporosis is the pathologic fracture of several skeletal 
sites of the body, such as proximal femur and hip, verte-
brae, distal forearm, proximal humerus, and pelvis (2). The 
susceptibility to low trauma fracture represents a major 
health burden in rapidly aging global population because 
it results in significant morbidity and mortality rates (2,3), 
and high health care costs (2,4). Epidemiologically, in the 
United States, about 9 million adults have been reported 
as osteoporotic, and 48 million have low bone mass lev-
els and are at a higher risk of developing osteoporosis (1). 
As the most expensive fracture, hip fracture is estimated to 
increase worldwide from 1.26 million in 1990 to 2.6 mil-
lion by 2025 and to 4.5 million by the year 2050 (2). Ac-
cording to the World Health Organization (WHO), a bone 
is called “osteoporotic” when its mineral density is 2.5 or 
more standard deviations (SD) below that of young normal 
population of the same sex, also referred to as a T-score of 
–2.5; 1.0 to 2.5 SDs decrease in bone mineral density is 
defined as “osteopenia”, actually a T-score between -1.0 
and -2.5; and a bone mineral densitometry (BMD) which is 
less than one SD below that of mean peak value in young 
adults of the same gender (T-score between 0.0 and -1.0), 
is a normal density (1).
There is inverse correlation between BMD and fracture 
risk; the lower the BMD, the higher the risk of fracture. Al-
though the risk of fracture is lower in the osteopenic group, 
a great percentage of fractures occur because the number 
of osteopenic individuals is much greater than that of the 
osteoporotic individuals (1). There are several risk factors 
for osteoporosis and osteopenia, such as genetics, low cal-
cium and vitamin D intake, smoking, thinness, menopause 
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status, hypercortisolism, hyperthyroidism, hyperpara-
thyroidism, alcohol abuse, immobilization, and the most 
common factor advanced age (4, 5). Several medications 
and supplementations are introduced for the prevention or 
treatment of osteoporosis, including medications like Alen-
dronate and hormone replacement therapy (6) and supple-
mentations like calcium, vitamin D, phosphorus, magne-
sium, protein, fluorine (7), and omega-3 (8-10). 
Because of the high prevalence of osteoporosis, its notice-
able morbidity and mortality rates, and economic burden 
of its consequences, it is necessary to investigate further 
medications for preventing and treating the disease. One 
of the above supplementations that is less studied and less 
used is omega-3.Animal and human researches indicate 
that omega-3 in optimal amounts can promote bone for-
mation, inhibit bone resorption, increase BMD (8-11), and 
modulate markers of bone resorption and formation (12-
14). Omega-3 also modulates inflammatory markers, such 
as tumor necrosis factor alpha (TNF-α), interleukin-1β 
(IL-1β), (interleukin-6)IL-6, and prostaglandin E2 (PGE2) 
(15). As the chronic senile disease of osteoporosis is as-
sociated with inflammation, inflammatory mediators can 
modulate the disease (8-10, 12, 15). Omega-3 supplemen-
tation is proved to be a treatment for osteoporosis, besides 
its further beneficial effects on other organs and in prevent-
ing other pathological conditions associated with the aging 
process, like cardiovascular diseases (16), depression (17), 
impairment of cognition, muscle tonus, and general health 
status (18).Therefore, the aim of this article is to undertake 
a review investigating the effect of omega-3 supplementa-
tion on modulating osteoporosis in the elderly.
Pathogenesis of Osteoporosis
Bone is a metabolically active organ that changes due to 
continuous modeling and remodeling process all through 
the life, modeling in response to biomechanical forces, and 
remodeling to eliminate old, micro-damaged bone and re-
place it with a stronger tissue. Decrease in bone density 
may be due to improper remodeling. Bone tissue include 
several type of cells, remodeling cells (osteoclasts), sup-
port cells (osteoblasts and osteocytes), and matrix proteins 
(osteoid) in which inorganic minerals are deposited. The 
precursor of the osteoblasts is mesenchymal stem cells. 
Osteoblastsare is responsible for matrix formation and 
its mineralization, and inhibiting osteoclasts’ ability in 
breaking down of the tissue. These cells have receptors for 
parathyroid hormone, estrogen, thyroid hormone, growth 
factors, and are also stimulated by physical activity.An or-
ganic phosphate-splitting enzyme, which attaches to the 
external surface of osteoblasts, is alkaline phosphatase. The 
serum level of alkaline phosphatase reflects bone metabo-
lism.Transforming into osteocytes is seen in some osteo-
blasts. Among all bone tissue cells, osteocytes function as 
the mechanoreceptors for bone,signaling osteoclasts forth-
eirreabsorption activity and osteoblasts for their formation 
activity. The only cells for bone resorption are osteoclasts, 
which originated from the hematopoietic stem cells, which 
also is the precursor of macrophages (19).
Various factors are known to play a role in differentiation 
of osteoclasts: hormones, growth factors, eicosanoids, im-
mune mediators;the endocrine, paracrine, and autocrine 
ways; inflammatory cytokines, interleukin-1 (IL-1), IL-6, 
and TNF-α;receptor activator of nuclear factor-kB ligand 
(RANKL) and its receptor, reactive oxygen species (ROS), 
and oxidative stress.IL-1 and TNF-a stimulate IL-6 pro-
duction, and are potent stimulators of bone resorption and 
inhibitors of bone formation. These three inflammatory cy-
tokines have been shown to be active in the pathogenesis of 
osteoporosis. RANKL and RANKL receptor, belonging to 
the TNF-α family, are present on the osteoblast membrane 
and their activation leads to osteoclastic differentiation and 
activation (19-22). Figure1 demonstrates the process of 
bone remodeling (23). 
The Main Mechanism of Action of Dietary Omega-3 
Fatty Acids on Bone 
Several animal and human studies demonstrate the preven-
tive or curative effects of polyunsaturated fatty acids (PU-
FAs) on osteoporosis (13, 14, 23-25). Menopause and aging 
lead to bone loss. Chronic inflammation due to aging can 
increase bone resorption and inhibit its synthesis (20, 26). 
The PUFAs are beneficial for bone health because of sev-
eral mechanisms, such as reducing inflammatory cytokines 
IL-1, IL-6, and TNF-α, modulation of peroxisome prolif-
erators-activated receptor γ (PPARγ), increasing calcium 
absorption, increasing skeletal calcium levels, change of 
membrane function, inhibition of osteoclastogenesis, and 
promoting osteoblastogenesis (27, 28).
One molecular mechanism involves PGE2 synthesis. Once 
mechanical load is applied to the bone, cell membranes 
release arachidonic acid, which then forms PGE2 as the 
expression of cyclooxygenase 2 (COX-2) increases. The 
PGE2 stimulates expression of RANK, RANKL and in-
hibits osteoprotegerin (OPG) expression, leading to osteo-
clastogenesis. It also activates the Wnt signaling pathway 
and insulin like growth factor-1 (IGF-1), leading to osteo-
blastogenesis. So, both formation and resorption processes 
are stimulated by PGE2. Generally, osteoblastogenesis as 
well as bone formation is promoted with the low levels of 
PGE2, while osteoclastogenesis and bone resorption result 
from high levels of PGE2 [28]. As eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) can modulatethe 
production of PGE2 and COX-2, osteoclastogenesis is 
suppressed and osteoblastogenesis is activated, resulting in 
bone health (16, 29). 
PPARγ is a nuclear transcription factor in fat tissue and 
bone marrow, resulting in suppression of osteoblastogene-
sis and bone loss. The n−6 polyunsaturated fatty acids can 
activate PPARγ (30).
There are two categories, structurally, for poly unsaturated 
fatty acids:n-3 (w-3, in which the third carbon from the 
methyl terminal is unsaturated) and n-6 (w-6, in which the 
sixth carbon from the methyl terminal is unsaturated) (30). 
Linoleic acid (LA) and α-linolenic acid (ALA) are essen-
tial fatty acids because humansdo not havethe ability to 
synthesize them, needing these FAs to be available in daily 
diet. Linoleic acid, found in high concentrations in various 
vegetable oils, is an n-6 PUFA that finally forms arachidon-
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ic acid (AA). Arachidonic acid is a precursor of prostaglan-
dins, leukotrienes,lipoxines, and P-450 compounds. The 
ALA, as a forerunner of EPA and DHA, is an n-3PUFA, 
mainly found in fish and fish oils. Because of low conver-
sion efficiency of ALA to EPA and DHA, supplementation 
with these FAs is recommended. The conversion of n-6 and 
n-3 polyunsaturated fatty acids to their longer chain forms 
is shown in Figure-2 (31).
Omega-6 and omega-3 fatty acids are present in phos-
pholipid membranes of cells and affect gene expression, 
functioning as precursors of eicosanoids (thromboxanes, 
prostaglandins, and leukotrienes). The n-6 FAs produce 
eicosanoids of atherogenic, proinflammatory, and vaso-
contrictive activity, more than that made of n-3 PUFAs. 
EPA and DHA have the most potent anti-inflammatory ef-
fects.Presence of EPA and DHA in cell membrane, results 
in reduced amount of n-6 fatty acids in the membranes; 
thus, reducing the presence of AA as well. A higher ratio of 
n-3/n-6 fatty acids in cell membranes can decrease the pro-
duction of inflammatory cytokines IL-1, IL-6, and TNF-α. 
So, essential fatty acids have inflammatory modulatory ef-
fects, and play a role in the pathogenesis of osteoporosis 
(3, 28, 30, 32, 33). 
MATERIALS AND METHODS
We reviewed randomized controlled trials (RCTs) reported 
in the literature from 1990 to 2017 in order to ascertain the 
appropriate dosage of omega-3 supplementation to treat 
and prevent osteoporosis in the elderly. Google scholar 
database was searched in May 2017 using the key words: 
n-3 fatty acids, omega-3 fatty acids, polyunsaturated fatty 
acids, essential fatty acids, eicosapentaenoic fatty acids, 
docosahexaenoic acid, docosapentaenoic acid, alpha lin-
olenic acid, linoleic acid, osteopenia, osteoporosis, bone 
density, and fracture.
 We reviewed English language reports of RCTs with in-
take of omega-3 PUFAs, in which subjects were over 60 
years and were supplemented with a quantified dosage of 
omega-3, not subjective and unmeasurable amounts like 
questionnaires and intake of seafood, and outcome was in-
dicated by bone mineral densitometry, medical record of 
fractures and radiological imaging, and serum biomarker 
to evaluate bone metabolism (bone formation markers like 
bone specific alkaline phosphatase (BSAP) and osteocalcin 
(OC), bone resorption markers like N-terminal telopeptide 
(NTx), C- terminal telopeptide (CTx), urinary pyridinoline 
(u-pyr) and urinary deoxypyridinoline (u-dpyr), and regu-
lators of bone turnover like osteoprotegerin (OPG), recep-
tor activator of NFkB ligand (RANKL), OPG/RANKL). 
There were no restrictions based on gender of the partici-
pants or race. Articles on cancer, autoimmune and inflam-
matory diseases, endocrinology diseases like diabetes and 
thyroid diseases, use of special medications like cortico-
steroids, hormones, gonadotropin-releasing hormone ana-
logue (GnRH analogs), anticonvulsive drugs, heparin, thy-
roid hormones, and smoking or alcohol consumption were 
excluded (Table1).
RESULTS
We reviewed 110 papers, of which onlyeight articles met 
our conclusion criteria. Only one concluded the curative 
effects (25). Three articles (34-36) came up with no pro-
phylactic or curative effects of omega-3 supplementation; 
three articles (9, 10, 37) suggested a dosage of omega-3 
supplement non-significantly, increasing BMD or decreas-
ing absorption, and thus, having prophylactic effects. One 
article just concluded the positive effects, not defining the 
exact results (38). Studies are summarized in table 1, with 
conclusion of studies and final results, which are further 
discussed in next part.
Several factors play a role in the results of the trials: the 
duration of taking supplementation, the exact components 
of supplementation and dosage, sufficient levels of vitamin 
D and daily calcium intake, sample size, heterogeneity of 
subjects including age, gender, race, and their pre-interven-
tion nutritional status.
DISCUSSION
According to our search and results, the only study with 
conclusion of the curative effect, conducted by Kruger et 
al. has several points to consider regarding its conclusion 
of having positive effects. Duration of intervention and fol-
low-up of the subjects is an important factor, as bone turn-
over is a gradual process and the resorption and formation 
activity in adult human bone takes about 3 to 4 months 
(39). In the first 18 months, only prophylactic effect of sup-
plementation was observed, and in the next 18 months, the 
curative effect was achieved. This shows that supplementa-
tion should continue for several months to observe results 
in bone density. Another point is participants’ osteoporot-
ic or osteopenic status and their mean age of 79.5, taking 
a background diet low in calcium. The fact that these old 
participants were somewhat malnourished, can explain the 
positive response to calcium and omega-3 supplementa-
tion in this study. Regarding ethnicity, they were Cauca-
sian South African women. So, the data and exact changes 
might not be applicable to other races, but it is not in con-
flict with the positive effects of omega-3 on skeletal health, 
because both treatment and placebo groups were from the 
same ethnicity, as its effect is proved in other animal and 
human researches.
According to results, lumbar spine density was the first to 
show increase in BMD in the first 18 months in 65 indi-
viduals, and in the next 18 months, femoral bone density 
increased in treatment group of 21 participants. Maybe the 
combination of fatty acid supplementation and 600 mg of 
calcium carbonate preferentially impact hip BMD. But it 
is not completely reliable because of the small number of 
samples (65 and 21 subjects). On the other hand, the pla-
cebo was coconut oil containing 97% saturated fat which 
might increase inflammatory factors in the placebo group, 
overestimating the effect of omega-3 supplementation (8). 
The study by Chen et al. (37) comes up with the prophy-
lactic effects. Over the two-year period, subjects received 
high dose (4.5g/d) and low dose (0.45 g/d) of omega-3 
fish oil. This study can be compared with Kruger’s (25). 
In Kruger’s study, significant prophylactic effect was ob-
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served in lumbar spine and curative effects in femoral neck 
by 6 mg/d of supplementation for 18 months, while in this 
study, the non-significant increase in lumbar spine densi-
ty and constant density of femoral neck was the outcome 
of 4.5 mg/d supplementation for 24 months. The fact that 
BMD did not decrease in 2 years and remained constant 
revealed the prophylactic effect of this dosage. It seems 
that Kruger’s dosage and formulation of supplement was 
more effective, but the smaller sample size of Kruger’s and 
the differences in gender, nationality, and the underlying 
disease of participants (osteoporosis and osteoarthritis) in 
both the studies should be taken into consideration.
The research conducted by Tartibian et al. (10) represents 
non-significant increase in BMD at lumbar site (L2-L4) and 
femoral neck by 24 weeks of 1000mg daily supplementa-
tion of omega-3. Levels of TNF-α, IL-6, PGE2, PTH, and 
C-telopepide decreased non-significantly, and calcitonin 
levels demonstrated a significant increase from the base-
line. Although these changes were almost non-significant, 
the trend increased the bone formation, decreased resorp-
tion, and attenuatedthe inflammatory factors, indicating 
the prophylactic, but not curative effects of 1000mg/day 
consumption of omega-3 for 24 weeks for post-menopaus-
al women. Maybe longer supplementation shows curative 
effects, similar to Kruger’s.
Sharif et al. (9) and Dong et al. (34) performed two studies 
of the same duration, but with a different formulation of 
supplement and individuals’ bone density status, placebo, 
sample size, and supplementation with calcium and vita-
min D. Dong et al. (34) supplemented both groups with 
calcium and vitamin D, while Sharif did not. Maybe these 
two supplements’ effect on bone health resulted in not hav-
ing between-group difference in Dong’s trial. And maybe 
the effect of calcium and vitamin D is equal to omega-3 
in 6 months, as it can also be concluded from Vanlint’s 
study (35). Sharif did not supplement the individuals with 
calcium and vitamin D, and the change in bone resorption 
markers was significantly different from control group, 
concluding that omega-3 has prophylactic effects.
LeBoff, et al. (38) conducted a VITAL-Bone Health study. 
The conclusion was that there is a relationship between 
supplemental vitamin D and / or omega-3 FAs on bone 
health outcomes. But no data was published in the article 
and no information on its effect on bone is available.
The studies by Vanlint and Appleton (35, 36) show no ef-
fect of supplementation and dosage on bone turnover. An-
other study by Appleton showed that the short duration of 
the study and individuals’ young ages may play a role in 
the result. In the study by Vanlint’s (35), the results showed 
that optimal supplementation of calcium and vitamin D 
can prevent osteoporosis, and addition of omega-3 did not 
demonstrate further effect which may be due to the small 
sample size.
CONCLUSION
Considering previous animal and human studies, there is 
great evidence that n-3 fatty acids have positive effects on 
bone density, but the form of FAs, dosage, and other factors 
seem to alter the effect.
Because of the small number of RCTs, short duration of 
supplementation, and the heterogeneity of studies, we are 
unable to make strong conclusions regarding the effect of 
n-3 FAs supplementation.
Notably, sufficient vitamin D and calcium intake is neces-
sary to achieve the greatest effect of omega-3 supplementa-
tion or even intake of calcium and vitamin D can have the 
same effect as omega-3, according to some articles previ-
ously mentioned (35,36,38).
It is important that subjects be supplemented and followed 
for several months, preferentially for several years and 
evaluated by BMD as well as serum biomarkers. Since ex-
ercise has synergic effect with omega-3, active or seden-
tary individuals should be evaluated in different groups. It 
is suggested that BMD be evaluated before starting supple-
mentation, because normal, osteopenic, and osteoporotic 
persons may respond differently to omega-3 intake, and the 
same DXA (dual X-ray absorptiometry). machine be used 
for all subjects throughout the study. Usage of medications 
like bisphosphonates should be considered.
Considering that supplementation needs to be continued 
for several months, the adverse effects of omega-3, even 
mild disturbances, should be noticed in order to prevent 
discontinuation of the treatment. Gastrointestinal upsets 
due to high doses of supplements was reported in some 
articles (25, 3). It is suggested that taking supplements ev-
ery other day, or weekly intake of high dose of omega-3 be 
evaluated, which seems to be more applicable for osteo-
penic or normal densityindividuals who want to prevent 
osteoporosis.
Recent studies have compared the efficacy of DHA and 
EPA. Some have concluded that DHA is more effective 
than EPA in modulating inflammatory markers (40, 41), 
while some concluded similar effects (42). Optimization 
of the ratio of EPA/DHA of supplements may provide en-
hanced protective potential.
We need more researches to see which formulation and 
dosage of omega-3 supplementation can have prophylac-
tic and curative effects. It is suggested that the dosage of 
4.5 to 6 g/d of EPA and DHA can have curative effects, 
while 900-1000 mg/d can have prophylactic outcomes. As 
the aim of omega-3 supplementation is to prevent or cure 
osteoporosis, it is recommended that the effects of high-
er dosage of supplementation (4.5-6g/d) for osteoporotic 
individuals as a curative drug, and lower dosage (900-
1000mg/d) for osteopenic individuals and normal ones as 
a prophylactic supplement be evaluated in future studies.
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